Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Real-time Estimate Cboe BZX 01:19:19 2024-04-16 pm EDT 5-day change 1st Jan Change
743.8 USD -0.93% Intraday chart for Eli Lilly and Company -1.84% +27.51%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Market sentiment sours Our Logo
Eli Lilly's $14 Million Insulin Settlement Shelved Amid Unfavorable Ruling MT
More than 250 websites selling fake weight-loss drugs reported by anti-counterfeit firm RE
European Medicines Agency Finds No Increased Suicide Risk Linked to Weight-loss Drugs MT
BMO Raises Price Target on Eli Lilly to $900 From $865 MT
EU regulator finds no link between weight-loss drugs and suicidal thoughts RE
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech MT
As You Sow Files an Exempt Solicitation Statement and Request Vote for the Proposal CI
Goldman Sachs Raises Price Target on Eli Lilly to $723 From $650, Maintains Neutral Rating MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech MT
Gerresheimer supplies 'key players' in GLP-1 drugs market, CEO says RE
Gerresheimer expects sales boost from burgeoning obesity drugs sector RE
Roche, Eli Lilly Alzheimer's Blood Test to Get Expedited FDA Review DJ
Roche, Eli Lilly's Elecsys Blood Test Secures US FDA's Breakthrough Device Designation MT
Sector Update: Health Care Stocks Decline Late Afternoon MT
Sector Update: Health Care Stocks Softer Monday Afternoon MT
Sector Update: Health Care MT
Eli Lilly Kicks Off Construction of Plant in Germany to Boost Weight-Loss Drug Production MT
Eli Lilly Starts Construction of EUR2.3 Billion Production Plant in Germany MT
Biograil ApS announced that it has received funding from a group of investors CI
Eli Lilly's Weight Loss Drug Faces US Shortage MT
Some doses of Lilly's Zepbound in short supply through April-end, US FDA says RE
Some doses of Lilly's Zepbound in limited availability, US FDA says RE
Eli Lilly's Mounjaro Faces Tight Supply for Some Doses Through April, FDA Says MT
Novo says Ozempic starter kits still not available in Germany in Q2 RE
Chart Eli Lilly and Company
More charts
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
750.8 USD
Average target price
812.9 USD
Spread / Average Target
+8.28%
Consensus
  1. Stock Market
  2. Equities
  3. LLY Stock
  4. News Eli Lilly and Company
  5. Eli Lilly and : Names Chief Information & Digital Officer